Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Cancer Discov. 2014 Mar 27;4(6):662–673. doi: 10.1158/2159-8290.CD-13-0846

Figure 2. EML4-ALK L1196M and G1269A mutations are sensitive to ceritinib in vitro.

Figure 2

A) GI50 values of cell survival assay for crizotinib or ceritinib in cell lines harboring L1196M or G1269A crizotinib resistant-mutations. B-D) H3122 CR1 (B), MGH021-4 (C) and MGH045 (D) cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the indicated proteins. E) Nude mice bearing MGH045 cell line were treated with 100 mg/kg crizotinib or ceritinib 25 mg/kg. Tumor volumes are presented as mean +- SD (n=6).